Clinical Trial Update: XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease [Phase 1]

View source ↗

Summary

Phase 1 trial of XL184 (cabozantinib) for relapsed/refractory multiple myeloma with bone disease has completed. The update indicates the study status but does n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• XL184 (cabozantinib) (cabozantinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED